Top Purchase Related
Home
>
Node
>
Subnode

Protease inhibitor Kaletra (Lopinavir/Ritonavir) : significance and role in antiretroviral therapy of HIV infection and AIDS

Galegov, G.A.

Antibiotiki i Khimioterapiia 52(1-2): 42-45

2007

ISSN/ISBN: 0235-2990
PMID: 18461809
Document Number: 613292

Document emailed within 1 workday
Secure & encrypted payments

Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Kuschak, D.; Mauss, S.; Schmutz, G.; Gantke, B. 2001: Simultaneous Determination of the New HIV Protease Inhibitor Lopinavir (ABT 378) and of Indinavir (1), Amprenavir, Saquinavir, Ritonavir (ABT 538) (2) and Nelfinavir (3) in Human Plasma by Gradient HPLC Clinical Laboratory 47(9-10): 471-477
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Vieira, C.S.; Bahamondes, M.V.; de Souza, R.M.; Brito, M.B.; Rocha Prandini, T.R.; Amaral, E.; Bahamondes, L.; Duarte, G.; Quintana, S.M.; Scaranari, C.; Ferriani, R.A. 2014: Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women Journal of Acquired Immune Deficiency Syndromes 66(4): 378-385
Gutiérrez, Félix.; Padilla, S.; Masiá, M.; Navarro, Aés.; Gallego, J.; Hernández, I.; Ramos, Jé.Manuel.; Martin-Hidalgo, A. 2004: Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations Antiviral Therapy 9(1): 105-113
Simpson, K.N.; Baran, R.W.; Kirbach, S.E.; Dietz, B. 2011: Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 14(8): 1048-1054
2000: Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy MMW Fortschritte der Medizin 142(3 Suppl): 41
Chong, K.T.; Pagano, P.J. 1997: In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates Antimicrobial Agents and ChemoTherapy 41(11): 2367-2373
Chrysos, G.; Mikros, S.; Kokkoris, S.; Pastelli, A.; Kontochristopoulos, G. 2007: Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient Journal of Drugs in Dermatology: Jdd 6(7): 742-743
Waters, L.J.; Moyle, G.; Bonora, S.; D'Avolio, A.; Else, L.; Mandalia, S.; Pozniak, A.; Nelson, M.; Gazzard, B.; Back, D.; Boffito, M. 2007: Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients Antiviral Therapy 12(5): 825-830
Sangraula, H.; Sharma, K.K.; Dwivedi, S. 2001: Antiretroviral protease inhibitor therapy leads to hyperglycaemia, hyperlipidaemia and lipodystrophy National Medical Journal of India 14(6): 347-348
Hoffmann, F.; Funk, M.; Linde, R.; Notheis, G.; Petropoulou, T.; Eberle, J.; Gürtler, L.; Belohradsky, B.H.; Wintergerst, U. 2002: Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection European Journal of Medical Research 7(7): 330-334
Bard, J-Marie.; Lassalle, Régis.; Capeau, J.; Bach-Ngohou, K.; Nazih-Sanderson, Fçoise.; Rémy, Gérard.; Reynes, J.; Ecobichon, J-Luc.; Savès, M.; Raffi, Fçois. 2006: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy Antiviral Therapy 11(3): 361-370
Hammer, S.M.; Vaida, F.; Bennett, K.K.; Holohan, M.K.; Sheiner, L.; Eron, J.J.; Wheat, L.Joseph.; Mitsuyasu, R.T.; Gulick, R.M.; Valentine, F.T.; Aberg, J.A.; Rogers, M.D.; Karol, C.N.; Saah, A.J.; Lewis, R.H.; Bessen, L.J.; Brosgart, C.; DeGruttola, V.; Mellors, J.W. 2002: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial JAMA 288(2): 169-180
Patel, A.K.; Patel, K.K.; Naik, E.; Jingyi Duan; Ranjan, R.; Patel, J.K.; Salihu, H.M. 2011: Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India Journal of the International Association of Physicians in Aids Care 10(2): 111-118
Marcelin, A.-G.; Flandre, P.; de Mendoza, C.; Roquebert, B.; Peytavin, G.; Valer, L.; Wirden, M.; Abbas, S.; Katlama, C.; Soriano, V.; Calvez, V. 2007: Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients Antiviral Therapy 12(2): 247-252
Manosuthi, W.; Sungkanuparph, S.; Ruxrungtham, K.; Prasithsirikul, W.; Athichathanabadi, C.; Tantisiriwat, W.; Bowonwatanuwong, C.; Chumpathat, N.; Chaovavanich, A. 2008: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir Journal of Acquired Immune Deficiency Syndromes 47(1): 127-129
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956
Saves, M.; Raffi, F.; Clevenbergh, P.; Marchou, B.; Waldner-Combernoux, A.; Morlat, P.; LeMoing, V.; Riviere, C.; Chene, G.; Leport, C.; The APROCOStudy Group, 2000: Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients Antimicrobial Agents and Chemotherapy 44(12): 3451-3455
Shihab, H.M.; Lutwama, F.; Piloya, T.; Castelnuovo, B.; Kambugu, A.D.; Colebunders, R. 2009: Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause? Journal of Infection in Developing Countries 3(5): 405-407